Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Sex-differences in [68Ga]Ga-DOTANOC biodistribution.

Leisser A, Lukic K, Nejabat M, Wadsak W, Mitterhauser M, Mayerhöfer M, Karnaikas G, Raderer M, Hacker M, Haug AR.

Nucl Med Biol. 2019 Aug 28;76-77:15-20. doi: 10.1016/j.nucmedbio.2019.08.005. [Epub ahead of print]

PMID:
31654811
2.

PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations.

Mayerhoefer ME, Prosch H, Beer L, Tamandl D, Beyer T, Hoeller C, Berzaczy D, Raderer M, Preusser M, Hochmair M, Kiesewetter B, Scheuba C, Ba-Ssalamah A, Karanikas G, Kesselbacher J, Prager G, Dieckmann K, Polterauer S, Weber M, Rausch I, Brauner B, Eidherr H, Wadsak W, Haug AR.

Eur J Nucl Med Mol Imaging. 2019 Aug 13. doi: 10.1007/s00259-019-04452-y. [Epub ahead of print]

PMID:
31410538
3.

Whole-Body [18F]FDG-PET/MRI vs. [18F]FDG-PET/CT in Malignant Melanoma.

Berzaczy D, Fueger B, Hoeller C, Haug AR, Staudenherz A, Berzaczy G, Weber M, Mayerhoefer ME.

Mol Imaging Biol. 2019 Jul 30. doi: 10.1007/s11307-019-01413-7. [Epub ahead of print]

PMID:
31363965
4.

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-Pentixafor-PET/MRI.

Haug AR, Leisser A, Wadsak W, Mitterhauser M, Pfaff S, Kropf S, Wester HJ, Hacker M, Hartenbach M, Kiesewetter-Wiederkehr B, Raderer M, Mayerhoefer ME.

Theranostics. 2019 May 27;9(12):3653-3658. doi: 10.7150/thno.31032. eCollection 2019.

5.

(R)-[18F]NEBIFQUINIDE: A promising new PET tracer for TSPO imaging.

Berroterán-Infante N, Kalina T, Fetty L, Janisch V, Velasco R, Vraka C, Hacker M, Haug AR, Pallitsch K, Wadsak W, Mitterhauser M.

Eur J Med Chem. 2019 Aug 15;176:410-418. doi: 10.1016/j.ejmech.2019.05.008. Epub 2019 May 10.

PMID:
31125895
6.

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.

Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H.

Clin Nucl Med. 2019 Jul;44(7):535-543. doi: 10.1097/RLU.0000000000002603.

PMID:
31021918
7.

[68Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery.

Li X, Yu W, Wollenweber T, Lu X, Wei Y, Beitzke D, Wadsak W, Kropf S, Wester HJ, Haug AR, Zhang X, Hacker M.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1616-1625. doi: 10.1007/s00259-019-04322-7. Epub 2019 Apr 19.

8.

Is there a reliable size cut-off for splenic involvement in lymphoma? A [18F]FDG-PET controlled study.

Berzaczy D, Haug AR, Raderer M, Kiesewetter B, Berzaczy G, Weber M, Mayerhoefer ME.

PLoS One. 2019 Mar 8;14(3):e0213551. doi: 10.1371/journal.pone.0213551. eCollection 2019.

9.

Dynamic [18F]FET-PET/MRI using standard MRI-based attenuation correction methods.

Rausch I, Zitterl A, Berroterán-Infante N, Rischka L, Prayer D, Fenchel M, Sareshgi RA, Haug AR, Hacker M, Beyer T, Traub-Weidinger T.

Eur Radiol. 2019 Aug;29(8):4276-4285. doi: 10.1007/s00330-018-5942-9. Epub 2019 Jan 11.

10.

Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.

Grubmüller B, Senn D, Kramer G, Baltzer P, D'Andrea D, Grubmüller KH, Mitterhauser M, Eidherr H, Haug AR, Wadsak W, Pfaff S, Shariat SF, Hacker M, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19.

11.

PSMA Ligand PET/MRI for Primary Prostate Cancer: Staging Performance and Clinical Impact.

Grubmüller B, Baltzer P, Hartenbach S, D'Andrea D, Helbich TH, Haug AR, Goldner GM, Wadsak W, Pfaff S, Mitterhauser M, Balber T, Berroteran-Infante N, Grahovac M, Babich J, Seitz C, Kramer G, Susani M, Mazal P, Kenner L, Shariat SF, Hacker M, Hartenbach M.

Clin Cancer Res. 2018 Dec 15;24(24):6300-6307. doi: 10.1158/1078-0432.CCR-18-0768. Epub 2018 Aug 23.

PMID:
30139879
12.

Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment.

Leisser A, Nejabat M, Hartenbach M, Agha Mohammadi Sareshgi R, Shariat S, Kramer G, Krainer M, Hacker M, Haug AR.

Oncotarget. 2018 Mar 5;9(22):16197-16204. doi: 10.18632/oncotarget.24610. eCollection 2018 Mar 23.

13.

Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma.

Hartenbach M, Weber S, Pilz M, Hartenbach S, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR, Albert NL.

Clin Nucl Med. 2018 Jul;43(7):477-481. doi: 10.1097/RLU.0000000000002092.

PMID:
29659390
14.

[11C]acetate PET as a tool for diagnosis of liver steatosis.

Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M, Kienbacher C, Trauner M, Hacker M, Haug AR.

Abdom Radiol (NY). 2018 Nov;43(11):2963-2969. doi: 10.1007/s00261-018-1558-4.

15.

Hematopoiesis is prognostic for toxicity and survival of 223Radium treatment in patients with metastatic castration-resistant prostate cancer.

Leisser A, Nejabat M, Hartenbach M, Duan H, Shariat SF, Kramer G, Krainer M, Hacker M, Haug AR.

Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:157.

PMID:
29324927
16.

Does elevated glucose metabolism correlate with higher cell density in Neurofibromatosis type 1 associated peripheral nerve sheath tumors?

Berzaczy D, Mayerhoefer ME, Azizi AA, Haug AR, Senn D, Beitzke D, Weber M, Traub-Weidinger T.

PLoS One. 2017 Dec 5;12(12):e0189093. doi: 10.1371/journal.pone.0189093. eCollection 2017.

17.

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26.

18.

Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas.

Poetsch N, Woehrer A, Gesperger J, Furtner J, Haug AR, Wilhelm D, Widhalm G, Karanikas G, Weber M, Rausch I, Mitterhauser M, Wadsak W, Hacker M, Preusser M, Traub-Weidinger T.

Neuro Oncol. 2018 Feb 19;20(3):411-419. doi: 10.1093/neuonc/nox177.

19.

Cold-Induced Brown Adipose Tissue Activity Alters Plasma Fatty Acids and Improves Glucose Metabolism in Men.

Iwen KA, Backhaus J, Cassens M, Waltl M, Hedesan OC, Merkel M, Heeren J, Sina C, Rademacher L, Windjäger A, Haug AR, Kiefer FW, Lehnert H, Schmid SM.

J Clin Endocrinol Metab. 2017 Nov 1;102(11):4226-4234. doi: 10.1210/jc.2017-01250.

PMID:
28945846
20.

[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques.

Li X, Heber D, Leike T, Beitzke D, Lu X, Zhang X, Wei Y, Mitterhauser M, Wadsak W, Kropf S, Wester HJ, Loewe C, Hacker M, Haug AR.

Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):558-566. doi: 10.1007/s00259-017-3831-0. Epub 2017 Sep 21.

21.

Imaging of primary liver tumors with positron-emission tomography.

Haug AR.

Q J Nucl Med Mol Imaging. 2017 Sep;61(3):292-300. doi: 10.23736/S1824-4785.17.02994-6. Review.

22.

Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients.

Berzaczy D, Giraudo C, Haug AR, Raderer M, Senn D, Karanikas G, Weber M, Mayerhoefer ME.

Clin Nucl Med. 2017 Sep;42(9):669-674. doi: 10.1097/RLU.0000000000001753.

23.

Efficacy of peptide receptor radionuclide therapy with 177Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.

Sabet A, Haug AR, Eiden C, Auernhammer CJ, Simon B, Bartenstein P, Biersack HJ, Ezziddin S.

Am J Nucl Med Mol Imaging. 2017 Apr 15;7(2):74-83. eCollection 2017.

24.

[Selective intraarterial radiotherapy (SIRT) of malignant liver tumors].

Müller SP, Ezziddin S, Antoch G, Lauenstein T, Amthauer H, Haug AR, Bockisch A.

Nuklearmedizin. 2017;56(5):162-170. doi: 10.3413/Nukmed-2017-05-0001. Epub 2018 Jan 4. German.

PMID:
29533422
25.

Effectiveness of Reduced Radioiodine Activity for Thyroid Remnant Ablation after Total Thyroidectomy in Patients with Low to Intermediate Risk Differentiated Thyroid Carcinoma.

Todica A, Haidvogl S, Fendler WP, Ilhan H, Rominger A, Haug AR, Bartenstein P, Lehner S.

Nuklearmedizin. 2017;56(6):211-218. doi: 10.3413/Nukmed-0922-17-08. Epub 2018 Jan 11.

PMID:
29533416
26.

Reply: High Impact of Preferential Flow on 99mTc-MAA and 90Y-Loaded Microsphere Uptake Correlation.

Haug AR, Ilhan H.

J Nucl Med. 2016 Nov;57(11):1830-1831. Epub 2016 Jun 30. No abstract available.

27.

Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy.

Ilhan H, Wang H, Gildehaus FJ, Wängler C, Herrler T, Todica A, Schlichtiger J, Cumming P, Bartenstein P, Hacker M, Haug AR.

EJNMMI Res. 2016 Dec;6(1):64. doi: 10.1186/s13550-016-0219-2. Epub 2016 Aug 11.

28.

Combined positron emission tomography/computed tomography (PET/CT) for imaging of orbital tumours and tumours extending into the orbit.

Klingenstein A, Mueller-Lisse GU, Haug AR, Garip-Kuebler A, Miller CV, Hintschich CR.

Br J Ophthalmol. 2016 Oct;100(10):1403-8. doi: 10.1136/bjophthalmol-2015-307988. Epub 2016 Jan 14.

PMID:
26769673
29.

Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.

Fendler WP, Lechner H, Todica A, Paprottka KJ, Paprottka PM, Jakobs TF, Michl M, Bartenstein P, Lehner S, Haug AR.

J Nucl Med. 2016 Apr;57(4):517-23. doi: 10.2967/jnumed.115.165050. Epub 2016 Jan 7.

30.

Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.

Spick C, Polanec SH, Mitterhauser M, Wadsak W, Anner P, Reiterits B, Haug AR, Hacker M, Beheshti M, Karanikas G.

Anticancer Res. 2015 Dec;35(12):6787-91. Erratum in: Anticancer Res. 2016 Feb;36(2):835.

PMID:
26637897
31.

Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using 18F-Fluoroethylcholine PET/CT.

Hartenbach M, Weber S, Albert NL, Hartenbach S, Hirtl A, Zacherl MJ, Paprottka PM, Tiling R, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Nov;56(11):1661-6. doi: 10.2967/jnumed.115.158758. Epub 2015 Sep 24.

32.

Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors.

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27.

33.

Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker.

Leisser A, Pruscha K, Ubl P, Wadsak W, Mayerhöfer M, Mitterhauser M, Hacker M, Kramer G, Shariat S, Karanikas G, Hartenbach M, Haug AR.

Prostate. 2015 Nov;75(15):1760-7. doi: 10.1002/pros.23061. Epub 2015 Aug 18.

PMID:
26282590
34.

Safety of Radioembolization with (90)Yttrium Resin Microspheres Depending on Coiling or No-Coiling of Aberrant/High-Risk Vessels.

Paprottka PM, Paprottka KJ, Walter A, Haug AR, Trumm CG, Lehner S, Fendler WP, Jakobs TF, Reiser MF, Zech CJ.

Cardiovasc Intervent Radiol. 2015 Aug;38(4):946-56. doi: 10.1007/s00270-015-1128-x. Epub 2015 May 20.

PMID:
25986465
35.

Nomogram including pretherapeutic parameters for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Ilhan H, Paprottka PM, Jakobs TF, Heinemann V, Bartenstein P, Khalaf F, Ezziddin S, Hacker M, Haug AR.

Eur Radiol. 2015 Sep;25(9):2693-700. doi: 10.1007/s00330-015-3658-7. Epub 2015 Feb 28.

PMID:
25721320
36.

Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization.

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2015 Mar;56(3):333-8. doi: 10.2967/jnumed.114.150565. Epub 2015 Feb 5.

37.

Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue.

Rachinger W, Stoecklein VM, Terpolilli NA, Haug AR, Ertl L, Pöschl J, Schüller U, Schichor C, Thon N, Tonn JC.

J Nucl Med. 2015 Mar;56(3):347-53. doi: 10.2967/jnumed.114.149120. Epub 2015 Jan 29.

38.

Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway.

Klingenstein A, Haug AR, Miller C, Hintschich C.

Orbit. 2015 Feb;34(1):16-22. doi: 10.3109/01676830.2014.959185. Epub 2014 Sep 29.

PMID:
25264824
39.

Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum.

Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR.

Ann Surg Oncol. 2015 Jan;22(1):164-71. doi: 10.1245/s10434-014-3981-2. Epub 2014 Sep 5.

PMID:
25190113
40.

Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography.

Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, Bartenstein P, Haug AR.

Mol Imaging. 2014;13:1-10.

PMID:
24824963
41.

Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases?

Ceelen F, Theisen D, de Albéniz XG, Auernhammer CJ, Haug AR, D'Anastasi M, Paprottka PM, Rist C, Reiser MF, Sommer WH.

J Magn Reson Imaging. 2015 Feb;41(2):361-8. doi: 10.1002/jmri.24569. Epub 2014 Jan 21.

PMID:
24446275
42.

The role of SPECT/CT in radioembolization of liver tumours.

Ahmadzadehfar H, Duan H, Haug AR, Walrand S, Hoffmann M.

Eur J Nucl Med Mol Imaging. 2014 May;41 Suppl 1:S115-24. doi: 10.1007/s00259-013-2675-5. Epub 2014 Jan 18. Review.

PMID:
24442600
43.

Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.

Michl M, Haug AR, Jakobs TF, Paprottka P, Hoffmann RT, Bartenstein P, Boeck S, Haas M, Laubender RP, Heinemann V.

Oncology. 2014;86(1):24-32. doi: 10.1159/000355821. Epub 2013 Dec 21.

PMID:
24401529
44.

Neuroendocrine tumor recurrence: diagnosis with 68Ga-DOTATATE PET/CT.

Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P, Hacker M.

Radiology. 2014 Feb;270(2):517-25. doi: 10.1148/radiol.13122501. Epub 2013 Oct 28.

PMID:
24056402
45.

Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin.

Sommer WH, Ceelen F, García-Albéniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D.

Eur Radiol. 2013 Nov;23(11):3094-103. doi: 10.1007/s00330-013-2925-8. Epub 2013 Jun 28.

PMID:
23807569
46.

Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.

Fendler WP, Philippe Tiega DB, Ilhan H, Paprottka PM, Heinemann V, Jakobs TF, Bartenstein P, Hacker M, Haug AR.

J Nucl Med. 2013 Aug;54(8):1202-8. doi: 10.2967/jnumed.112.116426. Epub 2013 May 31.

47.

Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.

Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators.

J Hepatol. 2013 Oct;59(4):753-61. doi: 10.1016/j.jhep.2013.05.025. Epub 2013 May 23.

PMID:
23707371
48.

Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas.

Schmid-Tannwald C, Schmid-Tannwald CM, Morelli JN, Neumann R, Haug AR, Jansen N, Nikolaou K, Schramm N, Reiser MF, Rist C.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):897-907. doi: 10.1007/s00259-013-2371-5. Epub 2013 Mar 5.

PMID:
23460395
49.

The role of 68Ga-DOTATATE PET/CT in suspected neuroendocrine tumors.

Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, Schmidt GP, Göke B, Bartenstein P, Hacker M.

J Nucl Med. 2012 Nov;53(11):1686-92. doi: 10.2967/jnumed.111.101675. Epub 2012 Sep 14.

50.

[Importance of PET/CT for imaging of colorectal cancer].

Meinel FG, Schramm N, Haug AR, Graser A, Reiser MF, Rist C.

Radiologe. 2012 Jun;52(6):529-36. doi: 10.1007/s00117-011-2284-x. German.

PMID:
22618625

Supplemental Content

Support Center